Trastuzumab emtansine (T-DM1), an antibody–drug conjugate (ADC) combining trastuzumab with the cytotoxic payload DM1, reduces off-target toxicity by selectively delivering chemotherapy to HER2-expressing tumor cells. This evidence concerns the gene ERBB2 and neoplasm.